Sunmax Biotechnology Co Ltd - Asset Resilience Ratio
Sunmax Biotechnology Co Ltd (4728) has an Asset Resilience Ratio of 10.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 4728 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sunmax Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See Sunmax Biotechnology Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sunmax Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sunmax Biotechnology Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$200.00 Million | 10.53% |
| Total Liquid Assets | NT$200.00 Million | 10.53% |
Asset Resilience Insights
- Moderate Liquidity: Sunmax Biotechnology Co Ltd has 10.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Sunmax Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sunmax Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sunmax Biotechnology Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sunmax Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.86% | NT$90.00 Million ≈ $2.84 Million |
NT$1.85 Billion ≈ $58.31 Million |
-0.10pp |
| 2023-12-31 | 4.96% | NT$107.10 Million ≈ $3.37 Million |
NT$2.16 Billion ≈ $68.02 Million |
-7.72pp |
| 2022-12-31 | 12.68% | NT$227.37 Million ≈ $7.16 Million |
NT$1.79 Billion ≈ $56.50 Million |
+7.50pp |
| 2021-12-31 | 5.17% | NT$76.79 Million ≈ $2.42 Million |
NT$1.48 Billion ≈ $46.75 Million |
-4.43pp |
| 2020-12-31 | 9.60% | NT$131.01 Million ≈ $4.13 Million |
NT$1.36 Billion ≈ $42.98 Million |
-3.38pp |
| 2019-12-31 | 12.98% | NT$144.42 Million ≈ $4.55 Million |
NT$1.11 Billion ≈ $35.05 Million |
-14.99pp |
| 2018-12-31 | 27.97% | NT$211.95 Million ≈ $6.68 Million |
NT$757.89 Million ≈ $23.88 Million |
+8.08pp |
| 2017-12-31 | 19.88% | NT$131.40 Million ≈ $4.14 Million |
NT$660.92 Million ≈ $20.82 Million |
+17.70pp |
| 2016-12-31 | 2.19% | NT$13.06 Million ≈ $411.43K |
NT$597.49 Million ≈ $18.82 Million |
-- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.